Join
Live feed
·
PRReleasevia Quantisnow
Editas Medicine Inc. logo

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

ByQuantisnow·Wall Street's wire, on your screen.
EDIT· Editas Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EDIT (Editas Medicine Inc.) and more on Quantisnow.